Reference compound for use in the analysis of levosimendan batches

• US 6,340,764 B1
• Filed: 02/20/2001
• Issued: 01/22/2002
• Est. Priority Date: 06/18/1998
• Status: Expired due to Term

• Current Assignee: Orion Corporation (Smiths Group International Holdings Ltd.)
• Original Assignee: Orion Corporation (Smiths Group International Holdings Ltd.)
• Inventors: Hauta-Aho, Tuula, Heinonen, Tuula, Bäckström, Reijo
• Primary Examiner(s): Higel, Floyd D.
• Assistant Examiner(s): SAEED, KAMAL A
• Application Number:
  US09/719,806
• Time in Patent Office: 336 Days
• Field of Search: 549/321, 514/473
• US Class Current: 549/321
• CPC Class Codes: C07D 307/33 in position 2, the oxygen atom being in its keto or unsubstituted enol form
• CPC Class Codes: G01N 30/04 Preparation or injection of sample to be analysed
• CPC Class Codes: Y10T 436/142222 Hetero-O [e.g., ascorbic acid, etc.]
• CPC Class Codes: Y10T 436/147777 Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Abstract

A pyridazinyl derivative (I) and its use as a reference compound in the determination of potentially genotoxic impurities in levosimendan samples. An analytic method for the determination of potentially genotoxic impurities in levosimendan samples wherein (I) is used as a reference compound. Levosimendan is a medicament useful in the treatment of heart failure.

Claims

1. A compound of formula I

2. A composition for the determination of potentially genotoxic impurities in a sample of levosimendan, which comprises a compound of claim 1.

3. A composition according to claim 2, containing no pyridazinyl compounds.

4. A composition for the determination of potentially genotoxic impurities in a sample of levosimendan, which comprises a compound of claim 1 together with an analytically acceptable carrier.

5. A composition according to claim 4, containing no pyridazinyl compounds.

6. An analytic method for the determination of potentially genotoxic impurities in a sample of levosimendan, which method comprises preparing a reference standard solution by dissolving a compound of claim 1 in solution, preparing a test solution by dissolving the sample of levosimendan in solution, obtaining a HPCL chromatogram of said reference standard solution, obtaining a HPLC chromatogram of said test solution and determining the concentration of compound of claim 1 in the sample.

7. An analytic method for the determination of potentially genotoxic impurities in a sample of levosimendan, which comprises comparing an analysis of composition as claimed in claim 2 to an analysis of the sample of levosimendan.

8. A method according to claim 7, wherein the analysis of the composition and the analysis of the sample of levosimendan is an HPLC analysis.

9. An HPLC chromatogram of composition as claimed in claim 2.

10. A method of determining the concentration of a compound of formula I in a sample of levosimendan,

which comprises comparing an analysis of a reference preparation as claimed in claim 2 to an analysis of the sample of levosimendan.

11. A method according to claim 10, wherein the analysis of the composition and the analysis of the sample of levosimendan is an HPLC analysis.

12. A mixture of compounds of formula I according to claim 1, wherein the compounds are of one diastereomer or a mixture of diastereomers.